15502-m-pleumeekers

403. Nguyen, D., et al., Cartilage Tissue Engineering by the 3D Bioprinting of iPS Cells in a Nanocellulose/Alginate Bioink. Sci Rep, 2017. 7 (1): p. 658. 404. Muller, M., et al., Alginate Sulfate-Nanocellulose Bioinks for Cartilage Bioprinting Applications. Ann Biomed Eng, 2017. 45 (1): p. 210-223. 405. Torres, F.G., S. Commeaux, and O.P. Troncoso, Biocompatibility of bacterial cellulose based biomaterials. J Funct Biomater, 2012. 3 (4): p. 864-78. 406. Cui, X., et al., Direct human cartilage repair using three-dimensional bioprinting technology. Tissue Eng Part A, 2012. 18 (11-12): p. 1304-12. 407. Lee, M.H., et al., Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. Tissue Eng Part B Rev, 2010. 16 (1): p. 41-54. 408. Commission., E., Regulation 1394/2007 for Advanced Therapy Medicinal Products. 2007. 409. FDA, U.S., Title 21 of the Code of Federal Regulations (CFR) Part 1271 Human Cells, Tissues and Cell and Tissue Based Products. 2001. 410. Abou-El-Enein, M., A. Elsanhoury, and P. Reinke, Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell, 2016. 19 (3): p. 293-7. 411. Yano, K., Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan. Regenerative Therapy, 2015. 1 : p. 45-56. 412. Liikanen, E., Commission directive 2003/94/European Commission. Official Journal of the European Union, 2003: p. 22-26. 413. Eaker, S., et al., Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing. Stem Cells Transl Med, 2013. 2 (11): p. 871-83. 414. Brittberg, M., Cellular and Acellular Approaches for Cartilage Repair: A Philosophical Analysis. Cartilage, 2015. 6 (2 Suppl): p. 4S-12S. 415. Lebourg, M., et al., Cell-free cartilage engineering approach using hyaluronic acid-polycaprolactone scaffolds: a study in vivo. J Biomater Appl, 2014. 28 (9): p. 1304-15. 219 REFERENCES